{"id":2626,"date":"2018-07-24T13:37:14","date_gmt":"2018-07-24T17:37:14","guid":{"rendered":"https:\/\/med.virginia.edu\/pathology\/?page_id=2626"},"modified":"2019-03-06T10:25:20","modified_gmt":"2019-03-06T15:25:20","slug":"charles-landen-m-d","status":"publish","type":"page","link":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/","title":{"rendered":"Charles Landen, M.D."},"content":{"rendered":"<p><a href=\"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-2600 size-medium\" src=\"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1-222x300.jpg\" alt=\"Charles Landen M.D.\" width=\"222\" height=\"300\" srcset=\"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1-222x300.jpg 222w, https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1-111x150.jpg 111w, https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1.jpg 240w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><br \/>\nAssociate Professor of Obstetrics and Gynecology<\/p>\n<h4>Education<\/h4>\n<ul class=\"fac-edu\">\n<li>BS, University of North Carolina at Chapel Hill<\/li>\n<li>MD, University of North Carolina at Chapel Hill<\/li>\n<li>MS, University of Texas Health Sciences Center, Houston<\/li>\n<\/ul>\n<h4>Contact<\/h4>\n<ul class=\"fac-details\">\n<li><strong>Phone:<\/strong> 243-6131<\/li>\n<li><strong>Email:<\/strong> <a href=\"mailto:cl3nj\">cl3nj<\/a><\/li>\n<\/ul>\n<h4>Research Interest(s)<\/h4>\n<p>Mechanisms of Chemotherapy Resistance in Ovarian and Other Gynecologic Malignancies<\/p>\n<h4>Research Description<\/h4>\n<p>Dr. Landen&#8217;s research focus is on novel therapeutics and chemotherapy resistance in gynecologic cancers, primarily ovarian cancer. He conducts preclinical and clinical research developing models to better-understand the pathways contributing to chemotherapy resistance and how recurrence develops. Mechanisms he has focused on include cancer stem cells, ABC transporters, and the Notch, Hedgehog, and Wnt pathways. His investigations have led to development of clinical trials seeking to overcome chemotherapy resistance. Clinically, his areas of interest include minimally invasive surgery, management of primary and recurrent ovarian cancer, and sentinel node dissections. He is the Associate Leader of the Women&#8217;s Oncology Program in the UVA Cancer Center.<\/p>\n<h4>Selected Publications<\/h4>\n<ul class=\"pubs\">\n<li>Arend R, Londo\u00f1o-Joshi A, Samant R, Li Y, Conner M, Hidalgo B, Alvarez R, Landen C, Straughn J, Buchsbaum D. Inhibition of Wnt\/\u03b2-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecologic oncology. 2014;134(1): 112-20. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24736023\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a024736023<\/a><\/li>\n<li>Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O&#8217;Connor M, Blumer J, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood A, Landen C, Eblen S. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014;35(5): 1100-9. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24379240\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a024379240<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4004201\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC4004201<\/a><\/li>\n<li>Dobbin Z, Katre A, Steg A, Erickson B, Shah M, Alvarez R, Conner M, Schneider D, Chen D, Landen C. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget. 2014;5(18): 8750-64. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25209969\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a025209969<\/a><\/li>\n<li>Dobbin Z, Landen C. Isolation and characterization of potential cancer stem cells from solid human tumors&#8211;potential applications. Current protocols in pharmacology \/ editorial board, S.J. Enna (editor-in-chief) &#8230; [et al.]. 2014;63 Unit 14.28.. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24510756\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a024510756<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4041697\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC4041697<\/a><\/li>\n<li>Shah M, Dobbin Z, Nowsheen S, Wielgos M, Katre A, Alvarez R, Konstantinopoulos P, Yang E, Landen C. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecologic oncology. 2014;134(2): 331-7. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24844596\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a024844596<\/a><\/li>\n<li>Steg A, Burke M, Amm H, Katre A, Dobbin Z, Jeong D, Landen C. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget. 2014;5(16): 7065-80. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25216523\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a025216523<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4196184\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC4196184<\/a><\/li>\n<li>Chen H, Landen C, Li Y, Alvarez R, Tollefsbol T. Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2\/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane. Journal of oncology. 2013;2013 872957. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23476648\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023476648<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3588178\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3588178<\/a><\/li>\n<li>Chen H, Landen C, Li Y, Alvarez R, Tollefsbol T. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Experimental cell research. 2013;319(5): 697-706. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23333498\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023333498<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3577973\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3577973<\/a><\/li>\n<li>Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Frontiers in oncology. 2013;3 251. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24069583\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a024069583<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3781360\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3781360<\/a><\/li>\n<li>Dobbin Z, Landen C. The Importance of the PI3K\/AKT\/MTOR Pathway in the Progression of Ovarian Cancer. International journal of molecular sciences. 2013;14(4): 8213-27. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23591839\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023591839<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3645739\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3645739<\/a><\/li>\n<li>Erickson B, Conner M, Landen C. The role of the fallopian tube in the origin of ovarian cancer. American journal of obstetrics and gynecology. 2013;209(5): 409-14. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23583217\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023583217<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3937451\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3937451<\/a><\/li>\n<li>Erickson B, Landen C, Conner M. Reply: To PMID 23583217. American journal of obstetrics and gynecology. 2013;209(4): 396. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23665249\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023665249<\/a><\/li>\n<li>Fauci J, Sabbatino F, Wang Y, Londo\u00f1o-Joshi A, Straughn J, Landen C, Ferrone S, Buchsbaum D. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic oncology. 2013;132(1): 203-10. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24216048\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a024216048<\/a><\/li>\n<li>Landen C, Lengyel E. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecologic oncology. 2013;130(1): 6-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23926600\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023926600<\/a><\/li>\n<li>Schultz M, Swindall A, Wright J, Sztul E, Landen C, Bellis S. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. Journal of ovarian research. 2013;6(1): 25. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23578204\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023578204<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3637436\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3637436<\/a><\/li>\n<li>Shah M, Landen C. Ovarian cancer stem cells: are they real and why are they important? Gynecologic oncology. 2013;132(2): 483-9. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24321398\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a024321398<\/a><\/li>\n<li>Kim K, Zsebik G, Straughn J, Landen C. Management of complex pelvic masses using a multivariate index assay: a decision analysis. Gynecologic oncology. 2012;126(3): 364-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22659191\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a022659191<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3696192\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3696192<\/a><\/li>\n<li>Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin Z, Li T, Hua X, Landen C, Birrer M, S\u00e1nchez-Beato M, Zhang R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Molecular cancer research : MCR. 2012;10(11): 1462-72. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22964433\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a022964433<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3501543\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3501543<\/a><\/li>\n<li>Qin Y, Xu J, Aysola K, Oprea G, Reddy A, Matthews R, Okoli J, Cantor A, Grizzle W, Partridge E, Reddy E, Landen C, Rao V. BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9. American journal of cancer research. 2012;2(5): 540-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22957306\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a022957306<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3433105\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3433105<\/a><\/li>\n<li>Steg A, Katre A, Bevis K, Ziebarth A, Dobbin Z, Shah M, Alvarez R, Landen C. Smoothened antagonists reverse taxane resistance in ovarian cancer. Molecular cancer therapeutics. 2012;11(7): 1587-97. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22553355\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a022553355<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3392529\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3392529<\/a><\/li>\n<li>Stone R, Nick A, McNeish I, Balkwill F, Han H, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena G, Pecot C, Coward J, Deavers M, Vasquez H, Urbauer D, Landen C, Hu W, Gershenson H, Matsuo K, Shahzad M, King E, Tekedereli I, Ozpolat B, Ahn E, Bond V, Wang R, Drew A, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf S, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood A. Paraneoplastic thrombocytosis in ovarian cancer. The New England journal of medicine. 2012;366(7): 610-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22335738\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a022335738<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3296780\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3296780<\/a><\/li>\n<li>Ziebarth A, Landen C, Alvarez R. Molecular\/genetic therapies in ovarian cancer: future opportunities and challenges. Clinical obstetrics and gynecology. 2012;55(1): 156-72. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22343235\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a022343235<\/a><\/li>\n<li>Ziebarth A, Nowsheen S, Steg A, Shah M, Katre A, Dobbin Z, Han H, Lopez-Berestein G, Sood A, Conner M, Yang E, Landen C. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;19(1): 170-82. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23147994\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a023147994<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3537868\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3537868<\/a><\/li>\n<li>Frederick P, Ramirez P, McQuinn L, Milam M, Weber D, Coleman R, Gershenson D, Landen C. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(5): 831-6. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21613957\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a021613957<\/a><\/li>\n<li>Nick A, Stone R, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill W, Landen C, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim H, Lee J, Kim S, Baggerly K, Ram P, Deavers M, Coleman R, Lopez-Berestein G, Sood A. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. Journal of the National Cancer Institute. 2011;103(21): 1596-612. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21957230\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a021957230<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3206039\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3206039<\/a><\/li>\n<li>Steg A, Bevis K, Katre A, Ziebarth A, Dobbin Z, Alvarez R, Zhang K, Conner M, Landen C. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;18(3): 869-81. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22142828\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a022142828<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3271164\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3271164<\/a><\/li>\n<li>Steg A, Katre A, Goodman B, Han H, Nick A, Stone R, Coleman R, Alvarez R, Lopez-Berestein G, Sood A, Landen C. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(17): 5674-85. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21753153\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a021753153<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3166981\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3166981<\/a><\/li>\n<li>Landen C, Goodman B, Katre A, Steg A, Nick A, Stone R, Miller L, Mejia P, Jennings N, Gershenson D, Bast R, Coleman R, Lopez-Berestein G, Sood A. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular cancer therapeutics. 2010;9(12): 3186-99. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20889728\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a020889728<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3005138\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3005138<\/a><\/li>\n<li>Merritt W, Kamat A, Hwang J, Bottsford-Miller J, Lu C, Lin Y, Coffey D, Spannuth W, Nugent E, Han L, Landen C, Nick A, Stone R, Coffman K, Bruckheimer E, Broaddus R, Gershenson D, Coleman R, Sood A. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer biology &amp; therapy. 2010;10(12): 1306-14. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20948320\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a020948320<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3047089\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3047089<\/a><\/li>\n<li>Worley M, Landen C, Slomovitz B, Malpica A, Palla S, Ramirez P. Expression of the retinoblastoma-related gene Rb2\/p130 in the pathogenesis of serous carcinoma of the ovary. Applied immunohistochemistry &amp; molecular morphology : AIMM \/ official publication of the Society for Applied Immunohistochemistry. 2010;18(6): 509-11. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20661130\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a020661130<\/a><\/li>\n<li>Kim T, Landen C, Lin Y, Mangala L, Lu C, Nick A, Stone R, Merritt W, Armaiz-Pena G, Jennings N, Coleman R, Tice D, Sood A. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer biology &amp; therapy. 2009;8(23): 2263-72. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19829059\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a019829059<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3400500\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3400500<\/a><\/li>\n<li>Lee J, Han H, Shahzad M, Kim S, Mangala L, Nick A, Lu C, Langley R, Schmandt R, Kim H, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice D, Landen C, Coleman R, Sood A. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute. 2009;101(17): 1193-205. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19641174\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a019641174<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2736292\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC2736292<\/a><\/li>\n<li>Lu C, Shahzad M, Moreno-Smith M, Lin Y, Jennings N, Allen J, Landen C, Mangala L, Armaiz-Pena G, Schmandt R, Nick A, Stone R, Jaffe R, Coleman R, Sood A. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer biology &amp; therapy. 2009;9(3): 176-82. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20009575\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a020009575<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3155813\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3155813<\/a><\/li>\n<li>Shahzad M, Lu C, Lee J, Stone R, Mitra R, Mangala L, Lu Y, Baggerly K, Danes C, Nick A, Halder J, Kim H, Vivas-Mejia P, Landen C, Lopez-Berestein G, Coleman R, Sood A. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer biology &amp; therapy. 2009;8(11): 1027-34. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19395869\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a019395869<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2748749\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC2748749<\/a><\/li>\n<li>Cole M, Broaddus R, Thaker P, Landen C, Freedman R. Placental-site trophoblastic tumors: a case of resistant pulmonary metastasis. Nature clinical practice. Oncology. 2008;5(3): 171-5. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18227827\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018227827<\/a><\/li>\n<li>Han L, Fletcher M, Urbauer D, Mueller P, Landen C, Kamat A, Lin Y, Merritt W, Spannuth W, Deavers M, De Geest K, Gershenson D, Lutgendorf S, Ferrone S, Sood A. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(11): 3372-9. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18519766\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018519766<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3426216\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3426216<\/a><\/li>\n<li>Landen C, Birrer M, Sood A. Early events in the pathogenesis of epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(6): 995-1005. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18195328\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018195328<\/a><\/li>\n<li>Landen C, Kim T, Lin Y, Merritt W, Kamat A, Han L, Spannuth W, Nick A, Jennnings N, Kinch M, Tice D, Sood A. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (New York, N.Y.). 2008;10(11): 1259-67. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18953435\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018953435<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2570602\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC2570602<\/a><\/li>\n<li>Lin Y, Immaneni A, Merritt W, Mangala L, Kim S, Shahzad M, Tsang Y, Armaiz-Pena G, Lu C, Kamat A, Han L, Spannuth W, Nick A, Landen C, Wong K, Gray M, Coleman R, Bodurka D, Brinkley W, Sood A. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(17): 5437-46. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18765535\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018765535<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2766914\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC2766914<\/a><\/li>\n<li>Lu C, Shahzad M, Wang H, Landen C, Kim S, Allen J, Nick A, Jennings N, Kinch M, Bar-Eli M, Sood A. EphA2 overexpression promotes ovarian cancer growth. Cancer biology &amp; therapy. 2008;7(7): 1098-103. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18443431\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018443431<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2705979\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC2705979<\/a><\/li>\n<li>Lu C, Thaker P, Lin Y, Spannuth W, Landen C, Merritt W, Jennings N, Langley R, Gershenson D, Yancopoulos G, Ellis L, Jaffe R, Coleman R, Sood A. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. American journal of obstetrics and gynecology. 2008;198(4): 477.e1-9; discussion 477.e9-10. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18395047\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018395047<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2346589\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC2346589<\/a><\/li>\n<li>Merritt W, Lin Y, Spannuth W, Fletcher M, Kamat A, Han L, Landen C, Jennings N, De Geest K, Langley R, Villares G, Sanguino A, Lutgendorf S, Lopez-Berestein G, Bar-Eli M, Sood A. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. Journal of the National Cancer Institute. 2008;100(5): 359-72. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18314475\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018314475<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2770251\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC2770251<\/a><\/li>\n<li>Kamat A, Kim T, Landen C, Lu C, Han L, Lin Y, Merritt W, Thaker P, Gershenson D, Bischoff F, Heymach J, Jaffe R, Coleman R, Sood A. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer research. 2007;67(1): 281-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17210709\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017210709<\/a><\/li>\n<li>Kamat A, Merritt W, Coffey D, Lin Y, Patel P, Broaddus R, Nugent E, Han L, Landen C, Spannuth W, Lu C, Coleman R, Gershenson D, Sood A. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(24): 7487-95. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18094433\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a018094433<\/a><\/li>\n<li>Kim T, Ravoori M, Landen C, Kamat A, Han L, Lu C, Lin Y, Merritt W, Jennings N, Spannuth W, Langley R, Gershenson D, Coleman R, Kundra V, Sood A. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer research. 2007;67(19): 9337-45. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17909042\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017909042<\/a><\/li>\n<li>Landen C, Lin Y, Armaiz Pena G, Das P, Arevalo J, Kamat A, Han L, Jennings N, Spannuth W, Thaker P, Lutgendorf S, Savary C, Sanguino A, Lopez-Berestein G, Cole S, Sood A. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer research. 2007;67(21): 10389-96. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17974982\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017974982<\/a><\/li>\n<li>Landen C, Lin Y, Immaneni A, Deavers M, Merritt W, Spannuth W, Bodurka D, Gershenson D, Brinkley W, Sood A. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(14): 4098-104. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17634535\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017634535<\/a><\/li>\n<li>Lu C, Kamat A, Lin Y, Merritt W, Landen C, Kim T, Spannuth W, Arumugam T, Han L, Jennings N, Logsdon C, Jaffe R, Coleman R, Sood A. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(14): 4209-17. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17634550\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017634550<\/a><\/li>\n<li>Ramirez P, Landen C, Coleman R, Milam M, Levenback C, Johnston T, Gershenson D. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecologic oncology. 2007;108(1): 68-71. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17905421\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017905421<\/a><\/li>\n<li>Halder J, Kamat A, Landen C, Han L, Lutgendorf S, Lin Y, Merritt W, Jennings N, Chavez-Reyes A, Coleman R, Gershenson D, Schmandt R, Cole S, Lopez-Berestein G, Sood A. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(16): 4916-24. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16914580\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016914580<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3144499\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3144499<\/a><\/li>\n<li>Han L, Landen C, Trevino J, Halder J, Lin Y, Kamat A, Kim T, Merritt W, Coleman R, Gershenson D, Shakespeare W, Wang Y, Sundaramoorth R, Metcalf C, Dalgarno D, Sawyer T, Gallick G, Sood A. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer research. 2006;66(17): 8633-9. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16951177\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016951177<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3202609\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3202609<\/a><\/li>\n<li>Kamat A, Bischoff F, Dang D, Baldwin M, Han L, Lin Y, Merritt W, Landen C, Lu C, Gershenson D, Simpson J, Sood A. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer biology &amp; therapy. 2006;5(10): 1369-74. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16969071\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016969071<\/a><\/li>\n<li>Kamat A, Fletcher M, Gruman L, Mueller P, Lopez A, Landen C, Han L, Gershenson D, Sood A. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(6): 1707-14. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16551853\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016551853<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3202606\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3202606<\/a><\/li>\n<li>Landen C, Lu C, Han L, Coffman K, Bruckheimer E, Halder J, Mangala L, Merritt W, Lin Y, Gao C, Schmandt R, Kamat A, Li Y, Thaker P, Gershenson D, Parikh N, Gallick G, Kinch M, Sood A. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Journal of the National Cancer Institute. 2006;98(21): 1558-70. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17077358\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017077358<\/a><\/li>\n<li>Landen C, Merritt W, Mangala L, Sanguino A, Bucana C, Lu C, Lin Y, Han L, Kamat A, Schmandt R, Coleman R, Gershenson D, Lopez-Berestein G, Sood A. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer biology &amp; therapy. 2006;5(12): 1708-13. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17106249\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017106249<\/a><\/li>\n<li>Lin Y, Han L, Kamat A, Merritt W, Landen C, Deavers M, Fletcher M, Urbauer D, Kinch M, Sood A. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2006;109(2): 332-40. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17154180\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a017154180<\/a><\/li>\n<li>Merritt W, Thaker P, Landen C, Deavers M, Fletcher M, Lin Y, Han L, Kamat A, Schmandt R, Gershenson D, Kinch M, Sood A. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer biology &amp; therapy. 2006;5(10): 1357-60. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16969087\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016969087<\/a><\/li>\n<li>Sood A, Bhatty R, Kamat A, Landen C, Han L, Thaker P, Li Y, Gershenson D, Lutgendorf S, Cole S. Stress hormone-mediated invasion of ovarian cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(2): 369-75. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16428474\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016428474<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3141061\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3141061<\/a><\/li>\n<li>Thaker P, Han L, Kamat A, Arevalo J, Takahashi R, Lu C, Jennings N, Armaiz-Pena G, Bankson J, Ravoori M, Merritt W, Lin Y, Mangala L, Kim T, Coleman R, Landen C, Li Y, Felix E, Sanguino A, Newman R, Lloyd M, Gershenson D, Kundra V, Lopez-Berestein G, Lutgendorf S, Cole S, Sood A. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature medicine. 2006;12(8): 939-44. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16862152\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016862152<\/a><\/li>\n<li>Halder J, Landen C, Lutgendorf S, Li Y, Jennings N, Fan D, Nelkin G, Schmandt R, Schaller M, Sood A. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(24): 8829-36. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16361572\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016361572<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3144933\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC3144933<\/a><\/li>\n<li>Han L, Landen C, Kamat A, Lopez A, Bender D, Mueller P, Schmandt R, Gershenson D, Sood A. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;24(5): 755-61. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16380413\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016380413<\/a><\/li>\n<li>Imai M, Landen C, Ohta R, Cheung N, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer research. 2005;65(22): 10562-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16288049\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016288049<\/a><\/li>\n<li>Landen C, Chavez-Reyes A, Bucana C, Schmandt R, Deavers M, Lopez-Berestein G, Sood A. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer research. 2005;65(15): 6910-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16061675\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016061675<\/a><\/li>\n<li>Landen C, Kinch M, Sood A. EphA2 as a target for ovarian cancer therapy. Expert opinion on therapeutic targets. 2005;9(6): 1179-87. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16300469\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a016300469<\/a><\/li>\n<li>Landen C, Klingelhutz A, Coffin J, Sorosky J, Sood A. Genomic instability is associated with lack of telomerase activation in ovarian cancer. Cancer biology &amp; therapy. 2004;3(12): 1250-3. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15477760\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a015477760<\/a><\/li>\n<li>Thaker P, Deavers M, Celestino J, Thornton A, Fletcher M, Landen C, Kinch M, Kiener P, Sood A. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(15): 5145-50. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15297418\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a015297418<\/a><\/li>\n<li>Landen C, Mathur S, Richardson M, Creasman W. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. American journal of obstetrics and gynecology. 2003;188(5): 1174-6. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12748469\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a012748469<\/a><\/li>\n<li>Landen C, Younger N, Collins Sharp B, Underwood P. Cancer patients&#8217; satisfaction with physicians: Princess Margaret Hospital Satisfaction with Doctor Questionnaire results. American journal of obstetrics and gynecology. 2003;188(5): 1177-9. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12748470\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a012748470<\/a><\/li>\n<li>Mathur S, Landen C, Datta S, Hoffman M, Mathur R, Young R. Insulin-like growth factor II in gynecological cancers: a preliminary study. American journal of reproductive immunology (New York, N.Y. : 1989). 2003;49(2): 113-9. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12765350\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a012765350<\/a><\/li>\n<li>Landen C, Zhang P, Young R. Differing mechanisms of inhibition of calcium increases in human uterine myocytes by indomethacin and nimesulide. American journal of obstetrics and gynecology. 2001;184(6): 1100-3. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11349169\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a011349169<\/a><\/li>\n<li>Vermillion S, Landen C. Prostaglandin inhibitors as tocolytic agents. Seminars in perinatology. 2001;25(4): 256-62. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11561913\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a011561913<\/a><\/li>\n<li>Liles D, Landen C, Monroe D, Lindley C, Read M, Roberts H, Brinkhous K. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thrombosis and haemostasis. 1997;77(5): 944-8. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9184407\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a09184407<\/a><\/li>\n<li>Fang B, Eisensmith R, Wang H, Kay M, Cross R, Landen C, Gordon G, Bellinger D, Read M, Hu P. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Human gene therapy. 1995;6(8): 1039-44. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7578416\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a07578416<\/a><\/li>\n<li>Kay M, Landen C, Rothenberg S, Taylor L, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson A. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(6): 2353-7. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8134398\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a08134398<\/a> | <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC43369\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMCID:\u00a0PMC43369<\/a><\/li>\n<li>Kay M, Rothenberg S, Landen C, Bellinger D, Leland F, Toman C, Finegold M, Thompson A, Read M, Brinkhous K. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science (New York, N.Y.). 1993;262(5130): 117-9. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8211118\/\" target=\"_BLANK\" rel=\"noopener noreferrer\">PMID:\u00a08211118<\/a><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Associate Professor of Obstetrics and Gynecology Education BS, University of North Carolina at Chapel Hill MD, University of North Carolina at Chapel Hill MS, University of Texas Health Sciences Center, Houston Contact Phone: 243-6131 Email: cl3nj Research Interest(s) Mechanisms of Chemotherapy Resistance in Ovarian and Other Gynecologic Malignancies Research Description Dr. Landen&#8217;s research focus is [&hellip;]<\/p>\n","protected":false},"author":1184,"featured_media":0,"parent":14,"menu_order":22,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"tags":[],"class_list":["post-2626","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Charles Landen, M.D. - Department of Pathology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles Landen, M.D. - Department of Pathology\" \/>\n<meta property=\"og:description\" content=\"Associate Professor of Obstetrics and Gynecology Education BS, University of North Carolina at Chapel Hill MD, University of North Carolina at Chapel Hill MS, University of Texas Health Sciences Center, Houston Contact Phone: 243-6131 Email: cl3nj Research Interest(s) Mechanisms of Chemotherapy Resistance in Ovarian and Other Gynecologic Malignancies Research Description Dr. Landen&#8217;s research focus is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Pathology\" \/>\n<meta property=\"article:modified_time\" content=\"2019-03-06T15:25:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1-222x300.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/\",\"url\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/\",\"name\":\"Charles Landen, M.D. - Department of Pathology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/wp-content\\\/uploads\\\/sites\\\/290\\\/2018\\\/07\\\/LandenC1-222x300.jpg\",\"datePublished\":\"2018-07-24T17:37:14+00:00\",\"dateModified\":\"2019-03-06T15:25:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/#primaryimage\",\"url\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/wp-content\\\/uploads\\\/sites\\\/290\\\/2018\\\/07\\\/LandenC1.jpg\",\"contentUrl\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/wp-content\\\/uploads\\\/sites\\\/290\\\/2018\\\/07\\\/LandenC1.jpg\",\"width\":240,\"height\":325,\"caption\":\"Charles Landen, M.D.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/charles-landen-m-d\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contact\",\"item\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/contact\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Charles Landen, M.D.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/#website\",\"url\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/\",\"name\":\"Department of Pathology\",\"description\":\"University of Virginia School of Medicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/med.virginia.edu\\\/pathology\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles Landen, M.D. - Department of Pathology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/","og_locale":"en_US","og_type":"article","og_title":"Charles Landen, M.D. - Department of Pathology","og_description":"Associate Professor of Obstetrics and Gynecology Education BS, University of North Carolina at Chapel Hill MD, University of North Carolina at Chapel Hill MS, University of Texas Health Sciences Center, Houston Contact Phone: 243-6131 Email: cl3nj Research Interest(s) Mechanisms of Chemotherapy Resistance in Ovarian and Other Gynecologic Malignancies Research Description Dr. Landen&#8217;s research focus is [&hellip;]","og_url":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/","og_site_name":"Department of Pathology","article_modified_time":"2019-03-06T15:25:20+00:00","og_image":[{"url":"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1-222x300.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/","url":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/","name":"Charles Landen, M.D. - Department of Pathology","isPartOf":{"@id":"https:\/\/med.virginia.edu\/pathology\/#website"},"primaryImageOfPage":{"@id":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/#primaryimage"},"image":{"@id":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/#primaryimage"},"thumbnailUrl":"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1-222x300.jpg","datePublished":"2018-07-24T17:37:14+00:00","dateModified":"2019-03-06T15:25:20+00:00","breadcrumb":{"@id":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/#primaryimage","url":"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1.jpg","contentUrl":"https:\/\/med.virginia.edu\/pathology\/wp-content\/uploads\/sites\/290\/2018\/07\/LandenC1.jpg","width":240,"height":325,"caption":"Charles Landen, M.D."},{"@type":"BreadcrumbList","@id":"https:\/\/med.virginia.edu\/pathology\/contact\/charles-landen-m-d\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/med.virginia.edu\/pathology\/"},{"@type":"ListItem","position":2,"name":"Contact","item":"https:\/\/med.virginia.edu\/pathology\/contact\/"},{"@type":"ListItem","position":3,"name":"Charles Landen, M.D."}]},{"@type":"WebSite","@id":"https:\/\/med.virginia.edu\/pathology\/#website","url":"https:\/\/med.virginia.edu\/pathology\/","name":"Department of Pathology","description":"University of Virginia School of Medicine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/med.virginia.edu\/pathology\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/pages\/2626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/users\/1184"}],"replies":[{"embeddable":true,"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/comments?post=2626"}],"version-history":[{"count":6,"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/pages\/2626\/revisions"}],"predecessor-version":[{"id":3394,"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/pages\/2626\/revisions\/3394"}],"up":[{"embeddable":true,"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/pages\/14"}],"wp:attachment":[{"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/media?parent=2626"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/med.virginia.edu\/pathology\/wp-json\/wp\/v2\/tags?post=2626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}